EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

Stephen W Chenard iD, Akhil Rekulapelli, Riley S Gilbertson, Connor S Charton, William F Hefley, Michael J Colello, Jennifer L Halpern, Herbert S Schwartz, Daniel J Johnson, Jonathan G Schoenecker, Joshua M Lawrenz

Journal of Surgical Oncology · 2026-06 · 133 (8) · 1089-1097

DOI: 10.1002/jso.70250 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 15.04.2026. Verfasst von Stephen W Chenard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, TN, USA. Hauptthemen laut MEDLINE: Plastic Surgery Procedures, Tranexamic Acid, Lower Extremity, Blood Loss, Surgical. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives While tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.

Methods

This retrospective single‐center study included 617 patients who underwent lower extremity endoprosthetic reconstruction for oncologic indications between 2000 and 2024. Patients were stratified by perioperative TXA administration ( n = 166) versus no TXA ( n = 451). The primary outcome was perioperative blood loss calculated using the Mercuriali method. Secondary outcomes included perioperative packed red blood cells (pRBC) transfusion, hospital length of stay, and 90‐day venous thromboembolic (VTE) complications.

Results

TXA was associated with a 429 mL reduction in calculated perioperative blood loss (1878 ± 1168 mL vs. 2307 ± 1442 mL; p = 0.003). TXA was not associated with reduced intraoperative pRBC transfusion rates (31% vs. 33%; RR 0.96 [95% CI: 0.74–1.25], p = 0.752) but was associated with significantly reduced postoperative transfusion requirements (17% vs. 30%; RR 0.56 [95% CI: 0.39–0.81], p = 0.003). No significant differences existed in 90‐day VTE complications, reoperation rates, or mortality.

Conclusions

Perioperative TXA use was associated with reduced blood loss and postoperative transfusion requirements without a detectable increase in thromboembolic complications, supporting TXA as a beneficial adjunct in musculoskeletal oncology limb salvage procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plastic Surgery ProceduresTranexamic AcidLower ExtremityBlood Loss, SurgicalAntifibrinolytic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultBone NeoplasmsFollow-Up Studies

Stichwörter der Autor:innen

blood transfusionlimb salvagepulmonary embolismsarcomavenous thromboembolismvenous thrombosis

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
  • Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN, USA.
  • Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.

ORCID-Profile: Stephen W Chenard

Zitieren

APA

Chenard, S. W., Rekulapelli, A., Gilbertson, R. S., Charton, C. S., Hefley, W. F., Colello, M. J., Halpern, J. L., Schwartz, H. S., Johnson, D. J., Schoenecker, J. G., & Lawrenz, J. M. (2026). Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients. Journal of Surgical Oncology, 133(8), 1089-1097. https://doi.org/10.1002/jso.70250

Vancouver

Chenard SW, Rekulapelli A, Gilbertson RS, Charton CS, Hefley WF, Colello MJ, et al. Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients. Journal of Surgical Oncology. 2026;133(8):1089-1097. doi:10.1002/jso.70250

BibTeX
@article{Chenard2026,
  author = {Chenard, Stephen W and Rekulapelli, Akhil and Gilbertson, Riley S and Charton, Connor S and Hefley, William F and Colello, Michael J and Halpern, Jennifer L and Schwartz, Herbert S and Johnson, Daniel J and Schoenecker, Jonathan G and Lawrenz, Joshua M},
  title = {Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  volume = {133},
  number = {8},
  pages = {1089--1097},
  doi = {10.1002/jso.70250}
}
Kostenlos starten →